Financial Reports Latest Updates Industry Maps Economic Calendar

Atara Biotherapeutics, Inc. (ATRA) Annual Reports

Q: Where can I read Atara Biotherapeutics, Inc. (ATRA) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Atara Biotherapeutics, Inc. is listed on Nasdaq, classified by the SEC under Biological Products, (No Diagnostic Substances) (SIC 2836). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1604464 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$630,000	$17.6M	-96.4%
Operating income	$-4.7M	$3.2M	-247.6%
Net income	$-4.8M	$2.4M	-302.5%
EPS (diluted)	$-0.32	$0.19	-268.4%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 0.63 mn Net income -4.83 mn

Show table：Income statement

Item	2013Q1	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	7.31	51.6	4.46	0.22	1.23	0.96	2.14	4.25	27.4	28.6	40.2	32.8	98.2	17.6	3.45	1.60	0.52	0.63
Operating income	-4.09	-2.55	-3.42	-7.08	-4.53	-5.95	-10.6	-9.31	-15.1	-12.3	-21.8	-17.1	-19.5	-25.9	-18.8	-26.2	-27.9	-31.7	-35.8	-42.5	-52.6	-60.2	-81.8	-67.9	-75.5	-72.6	-79.7	-74.7	-78.0	-74.7	-81.7	-78.2	-84.0	-84.8	-93.4	-88.2	-32.1	-84.6	-75.5	-75.0	-71.4	-69.6	-60.0	-31.3	-18.2	-21.8	-12.2	38.8	3.20	-3.57	-2.56	-3.37	-4.72
Net income	-4.11	-2.54	-3.56	-7.05	-4.51	-5.92	-10.5	-9.16	-14.9	-11.9	-21.3	-16.6	-18.9	-25.4	-18.2	-25.6	-27.4	-31.1	-35.3	-41.4	-50.9	-58.4	-80.0	-66.3	-74.3	-71.9	-78.5	-73.5	-77.5	-74.3	-81.3	-78.3	-83.8	-84.7	-93.3	-88.1	18.5	-84.1	-74.6	-74.8	-71.1	-69.8	-60.5	-31.8	-19.1	-21.9	-12.7	38.0	2.39	-4.30	-3.41	-4.14	-4.83

Balance sheet

Quarterly · In mn (USD)

Total assets 21.0 mn Total liabilities 58.0 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2013Q1	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	51.8	—	—	52.0	106	170	161	340	325	312	299	282	261	235	222	206	172	414	425	373	321	251	201	293	273	229	359	339	523	464	392	370	385	314	347	283	295	224	172	119	102	106	62.4	91.9	64.9	27.2	24.8	18.4	12.2	12.2	13.5
Total assets	—	—	51.8	—	—	54.1	106	170	161	340	325	313	301	284	264	242	244	230	218	473	493	443	392	325	274	365	343	300	428	406	588	530	457	450	468	397	436	368	376	302	246	189	166	165	117	143	109	62.0	36.9	30.2	20.2	20.0	21.0
Current liabilities	—	—	1.52	—	—	2.41	2.72	3.51	11.6	6.45	9.71	8.86	10.0	13.7	9.68	7.81	11.5	16.5	27.6	21.1	27.2	27.0	40.0	25.2	25.8	30.7	36.7	31.5	31.7	36.1	82.9	84.2	88.8	86.2	106	102	65.7	72.2	78.9	67.9	74.5	79.1	142	181	148	156	135	47.9	14.6	18.1	14.9	5.65	6.85
Total liabilities	—	—	1.75	—	—	2.58	2.94	3.72	11.8	6.63	9.88	9.14	10.6	14.2	10.2	8.60	23.0	23.7	39.9	33.9	40.2	39.9	53.0	40.8	41.9	46.3	52.2	46.7	47.0	51.6	126	131	125	140	189	173	179	181	250	237	239	240	265	264	228	233	206	117	71.9	66.8	58.7	57.3	58.0
Equity	-3.73	—	-11.0	—	—	-23.0	103	166	149	334	315	304	290	270	254	233	221	206	178	439	453	403	339	284	232	318	291	253	381	354	462	399	332	310	280	224	257	187	127	65.0	7.45	-50.8	-99.2	-98.3	-111	-90.5	-97.3	-55.1	-35.0	-36.6	-38.5	-37.3	-37.0

Cash flow

Quarterly · In mn (USD)

Operating -3.34 mn Investing -6.63 mn Financing 4.83 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2013Q1	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-0.82	-3.48	-2.49	-2.92	-4.66	-4.09	-4.96	-6.62	-6.24	-12.9	-11.4	-12.5	-10.8	-15.6	-21.2	-22.0	-20.3	-20.2	-24.9	-34.8	-39.4	-48.1	-57.4	-70.2	-54.6	-52.1	-58.7	-67.0	-56.6	-53.0	-4.12	-65.7	-61.6	-59.0	-34.3	-84.5	-64.0	-65.1	-56.9	-38.4	-52.8	-51.4	-50.4	-29.6	-10.6	-3.99	-24.5	-28.1	-7.32	-9.79	-5.70	-3.07	-3.34
Investing	-0.01	0	0	-22.4	-2.58	-1.44	-56.9	-13.4	-34.4	-153	-19.4	10.9	15.1	35.0	22.8	36.8	13.5	6.62	43.0	-250	-3.88	11.4	46.1	67.6	50.3	-58.5	1.13	39.0	-130	7.56	-36.9	13.5	31.9	1.19	-24.3	60.2	31.8	59.7	51.2	-6.01	49.5	70.5	9.94	14.7	7.20	-16.7	3.38	17.2	-5.07	-2.42	8.44	0	-6.63
Financing	5.04	15.0	38.4	13.5	-0.74	-0.55	58.1	69.5	-4.51	194	0.19	-0.02	-0.01	0.2	0.33	-0.33	9.81	9.87	0.7	296	56.0	-0.51	6.02	-1.93	7.33	146	37.5	24.0	191	33.5	179	2.89	2.45	47.1	51.5	19.9	1.16	-0.21	32.3	0.24	0.47	-0.21	1.51	24.1	-0.32	35.8	-0.33	-0.25	15.3	1.05	0	2.95	4.83
Cash at period end	4.21	15.7	51.6	39.8	31.8	25.7	21.9	71.3	26.2	54.5	23.8	22.1	26.4	46.0	48.0	62.4	64.2	60.5	79.2	90.5	103	66.0	60.7	56.2	59.2	94.4	74.3	70.2	74.5	62.6	200	151	124	113	106	102	70.7	65.1	92.9	48.7	45.9	64.8	25.8	35.1	31.3	46.5	25.0	13.8	16.9	5.74	8.48	8.36	3.22

Profitability

Quarterly · %

Operating margin -749.2% Net margin -767.3%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2013Q1	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-1206.2%	-62.3%	-1897.8%	-34180.5%	-6118.9%	-7462.3%	-3255.9%	-1410.2%	-114.2%	-63.7%	-54.1%	-37.3%	39.5%	18.2%	-103.5%	-160.7%	-652.9%	-749.2%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-1204.6%	35.8%	-1885.9%	-33743.0%	-6098.8%	-7430.3%	-3264.6%	-1421.7%	-116.1%	-66.5%	-54.5%	-38.8%	38.7%	13.6%	-124.6%	-213.5%	-803.3%	-767.3%

Returns & leverage

Quarterly · %

ROE -2014.9% ROA -57.6% Debt ratio 276.0%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2013Q1	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	-60.8%	-18.1%	-27.2%	-29.9%	-27.4%	-27.5%	-31.2%	-27.2%	-27.8%	-32.8%	-37.8%	-43.0%	-55.4%	-40.2%	-47.1%	-61.1%	-89.3%	-70.7%	-81.5%	-81.1%	-92.4%	-111.1%	-98.3%	-90.4%	-81.4%	-95.6%	-89.2%	-98.8%	-91.7%	-112.3%	-84.1%	-99.4%	-112.4%	-148.6%	-229.9%	-426.0%	-2014.9%	—	—	—	—	—	—	—	—	—	—
ROA	—	—	—	—	—	-38.9%	-35.5%	-17.7%	-25.2%	-23.6%	-26.6%	-26.8%	-29.7%	-26.3%	-26.9%	-31.8%	-35.5%	-39.8%	-49.6%	-37.9%	-43.1%	-55.3%	-75.7%	-64.0%	-72.8%	-72.4%	-79.2%	-95.5%	-85.8%	-78.9%	-65.9%	-75.1%	-71.8%	-76.7%	-64.4%	-75.5%	-55.5%	-60.4%	-54.1%	-61.5%	-89.2%	-104.2%	-101.9%	-99.8%	-99.5%	-80.3%	-62.2%	-13.8%	7.5%	27.1%	50.5%	-23.1%	-57.6%
Debt ratio	—	—	3.4%	—	—	4.8%	2.8%	2.2%	7.3%	1.9%	3.0%	2.9%	3.5%	5.0%	3.9%	3.6%	9.4%	10.3%	18.3%	7.2%	8.2%	9.0%	13.5%	12.6%	15.3%	12.7%	15.2%	15.6%	11.0%	12.7%	21.4%	24.7%	27.4%	31.1%	40.3%	43.5%	41.0%	49.2%	66.4%	78.5%	97.0%	126.9%	160.0%	159.5%	194.5%	163.4%	189.2%	188.8%	195.0%	221.4%	290.3%	286.6%	276.0%

EPS

Quarterly · US$

EPS US$-0.32

Show table：EPS

Item	2013Q1	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-4.15	—	-0.91	-0.90	-0.96	-0.87	0.18	-0.82	-0.73	-0.72	-0.68	-0.66	-0.56	-0.23	-3.10	-2.93	-0.07	3.50	0.19	-0.32	-0.36	-0.29	-0.32

Revenue & profit

Year-to-date · In mn (USD)

Revenue 1.15 mn Net income -8.98 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 21.0 mn Total liabilities 58.0 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -6.41 mn Investing -6.63 mn Financing 7.78 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -705.9% Net margin -783.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -2014.9% ROA -57.6% Debt ratio 276.0%

EPS

Year-to-date · US$

EPS US$-0.61

Revenue & profit

Annual · In mn (USD)

Revenue 121 mn Net income 32.7 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	—	—	—	—	—	—	—	63.6	8.57	129	121
Operating income	-28.2	-58.5	-81.2	-122	-237	-296	-309	-340	-281	-276	-83.4	35.9
Net income	-28.0	-57.2	-79.0	-119	-231	-291	-307	-340	-228	-276	-85.4	32.7

Balance sheet

Annual · In mn (USD)

Total assets 20.2 mn Total liabilities 58.7 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	106	325	261	172	321	273	523	385	295	102	64.9	12.2
Total assets	106	325	264	218	392	343	588	468	376	166	109	20.2
Current liabilities	2.72	9.71	9.68	27.6	40.0	36.7	82.9	106	78.9	142	135	14.9
Total liabilities	2.94	9.88	10.2	39.9	53.0	52.2	126	189	250	265	206	58.7
Equity	103	315	254	178	339	291	462	280	127	-99.2	-97.3	-38.5

Cash flow

Annual · In mn (USD)

Operating -50.9 mn Investing 18.1 mn Financing 16.1 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-16.6	-37.2	-60.0	-87.5	-180	-236	-181	-221	-270	-193	-68.7	-50.9
Investing	-83.4	-220	83.7	99.9	-196	60.5	-121	22.3	203	124	8.62	18.1
Financing	70.3	259	0.51	20.1	358	189	428	104	53.1	2.01	59.3	16.1
Cash at period end	21.9	23.8	48.0	79.2	60.7	74.3	200	106	92.9	25.8	25.0	8.48

Profitability

Annual · %

Operating margin 29.7% Net margin 27.1%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	—	—	—	—	—	—	—	-441.3%	-3219.5%	-64.7%	29.7%
Net margin	—	—	—	—	—	—	—	—	-359.1%	-3220.9%	-66.2%	27.1%

Returns & leverage

Annual · %

ROE -2014.9% ROA 50.5% Debt ratio 290.3%

Show table：Returns & leverage

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	-27.1%	-27.4%	-27.8%	-55.4%	-89.3%	-92.4%	-81.4%	-91.7%	-112.4%	-2014.9%	—	—
ROA	-26.4%	-26.6%	-26.9%	-49.6%	-75.7%	-79.2%	-65.9%	-64.4%	-54.1%	-101.9%	-62.2%	50.5%
Debt ratio	2.8%	3.0%	3.9%	18.3%	13.5%	15.2%	21.4%	40.3%	66.4%	160.0%	189.2%	290.3%

EPS

Annual · US$

EPS US$3.01

Show table：EPS

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	—	—	-2.24	-2.62	-6.33	3.01

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Atara Biotherapeutics, Inc. (ATRA) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.